ALC vs BBIO
Alcon Inc vs BridgeBio Pharma, Inc. — AI-powered side-by-side comparison
VS
BBIO
BridgeBio Pharma, Inc.
65
Insufficient Data
| Metric | ALC | BBIO |
|---|
| AI Score |
68
|
65
|
| Price |
$75.39
|
$83.71
|
| P/E Ratio |
45.39×
|
-23.38×
|
| ROE |
4.4%
|
35.1%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
93.1%
|
| Debt / Equity |
0.24×
|
-0.99×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
56.9
|
| Beta |
0.703
|
0.983
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus BBIO.
ALC leads by 3 points.
ALC scores 68/100 (Buy) versus BBIO at 65/100 (Insufficient Data).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
BBIO Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical